Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand

© 2014, Yamwong et al.; licensee Springer. Objectives: To evaluate the long-term cost-effectiveness of ticagrelor and ASA versus generic and branded clopidogrel and ASA in patients with ACS based on a Thai cost database. Methods: A one-year decision tree and a long-term Markov model were constructed...

Full description

Saved in:
Bibliographic Details
Main Authors: Sukit Yamwong, Unchalee Permsuwan, Sirana Tinmanee, Piyamitr Sritara
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84971330865&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/53707
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-53707
record_format dspace
spelling th-cmuir.6653943832-537072018-09-04T09:56:14Z Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand Sukit Yamwong Unchalee Permsuwan Sirana Tinmanee Piyamitr Sritara Medicine © 2014, Yamwong et al.; licensee Springer. Objectives: To evaluate the long-term cost-effectiveness of ticagrelor and ASA versus generic and branded clopidogrel and ASA in patients with ACS based on a Thai cost database. Methods: A one-year decision tree and a long-term Markov model were constructed to estimate lifetime costs and quality-adjusted life years (QALYs). For the first year, data from PLATO (NCT00391872) were used to estimate the rate of cardiovascular events, resource use, and QALYs. For year 2 onwards, clinical effectiveness was estimated conditional on individual health states that occurred during the first year. Results: In the base-case analysis, the incremental cost-effectiveness ratio (ICER) with ticagrelor was 292,504 ($9,476) and 60,055 ($1,946) THB($)/QALY compared with generic and branded clopidogrel, respectively. The probability of ticagrelor being cost-effective was above 99% at a threshold of 160,000 THB/QALY compared with branded clopidogrel. Conclusions: This health economic analysis provides cost effectiveness data for ticagrelor compared with both generic and branded clopidogrel in Thailand. Based on this analysis, it appears that ticagrelor is an economically valuable treatment for ACS compared with branded clopidogrel within the Thai context. 2018-09-04T09:56:14Z 2018-09-04T09:56:14Z 2014-12-01 Journal 21911991 2-s2.0-84971330865 10.1186/s13561-014-0017-3 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84971330865&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/53707
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
spellingShingle Medicine
Sukit Yamwong
Unchalee Permsuwan
Sirana Tinmanee
Piyamitr Sritara
Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
description © 2014, Yamwong et al.; licensee Springer. Objectives: To evaluate the long-term cost-effectiveness of ticagrelor and ASA versus generic and branded clopidogrel and ASA in patients with ACS based on a Thai cost database. Methods: A one-year decision tree and a long-term Markov model were constructed to estimate lifetime costs and quality-adjusted life years (QALYs). For the first year, data from PLATO (NCT00391872) were used to estimate the rate of cardiovascular events, resource use, and QALYs. For year 2 onwards, clinical effectiveness was estimated conditional on individual health states that occurred during the first year. Results: In the base-case analysis, the incremental cost-effectiveness ratio (ICER) with ticagrelor was 292,504 ($9,476) and 60,055 ($1,946) THB($)/QALY compared with generic and branded clopidogrel, respectively. The probability of ticagrelor being cost-effective was above 99% at a threshold of 160,000 THB/QALY compared with branded clopidogrel. Conclusions: This health economic analysis provides cost effectiveness data for ticagrelor compared with both generic and branded clopidogrel in Thailand. Based on this analysis, it appears that ticagrelor is an economically valuable treatment for ACS compared with branded clopidogrel within the Thai context.
format Journal
author Sukit Yamwong
Unchalee Permsuwan
Sirana Tinmanee
Piyamitr Sritara
author_facet Sukit Yamwong
Unchalee Permsuwan
Sirana Tinmanee
Piyamitr Sritara
author_sort Sukit Yamwong
title Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
title_short Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
title_full Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
title_fullStr Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
title_full_unstemmed Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
title_sort long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in thailand
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84971330865&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/53707
_version_ 1681424185339936768